Drugs / CD19.CAR-CD28Z T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02050347 | Apr 2014 → Oct 2019 overdue | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19.CAR-CD28Z T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02050347 ↗ |
| Modality | Cell therapy | “These CD19/CD28 chimeric receptor T cells are investigational products not approved by the FDA.” NCT02050347 ↗ |
| Route | Intravenous | “The subject will be given an injection of cells into the vein through an IV at the assigned dose.” NCT02050347 ↗ |